$9B Actos Bladder Cancer Settlement Gets Reduced to $37 Million

Lawyers and Settlements
October 28, 2014

[…] Doherty denied a motion by the defendants for a new trial and concluded that the punitive damages award was not “unreasonable given the evidence presented of a high degree of reprehensibility of the defendants’ conduct and the need to adequately deter such conduct in the future.” […] Actos, also known as pioglitazone hydrochloride, is a member of a class of drugs known as thiazolidinediones, which have been linked to bladder cancer, liver disease and cardiovascular issues. […]